Katrijn Bogman
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Prospective DDI Risk Assessment of Vicasinabin with PBPK Modeling by Integrating In Vitro Data.
Journal: Clinical pharmacology and therapeutics
Published: December 19, 2024
Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema.
Journal: Translational vision science & technology
Published: November 13, 2024
Ocular Pharmacokinetics of Faricimab Following Intravitreal Administration in Patients With Retinal Disease.
Journal: Translational vision science & technology
Published: November 13, 2024
CANBERRA: A Phase II Randomized Clinical Trial to Test the Therapeutic Potential of Oral Vicasinabin in Diabetic Retinopathy.
Journal: Ophthalmology science
Published: July 22, 2024
Assessment of Drug-Drug Interactions between Taspoglutide, a Glucagon-Like Peptide-1 Agonist, and Drugs Commonly Used in Type 2 Diabetes Mellitus: Results of Five Phase I Trials.
Journal: Clinical pharmacokinetics
Published: April 11, 2019
Effect of alectinib on cardiac electrophysiology: results from intensive electrocardiogram monitoring from the pivotal phase II NP28761 and NP28673 studies.
Journal: Cancer chemotherapy and pharmacology
Published: December 19, 2016
Effect of Food and Esomeprazole on the Pharmacokinetics of Alectinib, a Highly Selective ALK Inhibitor, in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: May 23, 2016
Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: May 17, 2016
Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
Journal: Hypertension (Dallas, Tex. : 1979)
Published: April 28, 2016
Clinical Drug-Drug Interactions Through Cytochrome P450 3A (CYP3A) for the Selective ALK Inhibitor Alectinib.
Journal: Clinical pharmacology in drug development
Published: April 08, 2016
Effect of the Wetting Agent Sodium Lauryl Sulfate on the Pharmacokinetics of Alectinib: Results From a Bioequivalence Study in Healthy Subjects.
Journal: Clinical pharmacology in drug development
Published: March 15, 2016
Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients.
Journal: European journal of clinical pharmacology
Published: July 10, 2009
Showing 1-12 of 12
Last Updated: 09/26/2026